Bioorganic and Medicinal Chemistry p. 2115 - 2137 (2004)
Update date:2022-08-05
Topics:
Takami, Atsuya
Iwakubo, Masayuki
Okada, Yuji
Kawata, Takehisa
Odai, Hideharu
Takahashi, Nobuaki
Shindo, Kazutoshi
Kimura, Kaname
Tagami, Yoshimichi
Miyake, Mika
Fukushima, Kayoko
Inagaki, Masaki
Amano, Mutsuki
Kaibuchi, Kozo
Iijima, Hiroshi
Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.
View MoreBeijing Century Richap Chemistry Co.,Ltd
Contact:+86- 010-64455497
Address:Guannan County, Lianyungang City, Jiangsu Province, China
Suzhou Lixin Pharmaceutical Co., Ltd.
Contact:86-512-88169812
Address:21 Tangxi Road, Suzhou New District, Suzhou 215151
Daicel Chiral Technologies (China)CO.,LTD
Contact:021-5046-0086*8
Address:Part C, FL 5, the 16th Building, No. 69, XiYa Road, WaiGaoQiao Free Trade Zone, Shanghai, 200131, P.R.China
Wuhan Better Organic Technology Inc.
Contact:13307163183
Address:Wuhan Economic&Technology Development Zone, Hubei
Yicheng Goto Pharmaceuticals Co.,Ltd.
Contact:+86 710 3423122
Address:5th Floor,East Gate of Building #2,Servo-Industrial Park,1st Qilin Road,Xiangyang,Hubei,China
Doi:10.1007/BF01431320
(1996)Doi:10.1039/dt9960002857
(1996)Doi:10.1002/adsc.201500255
(2015)Doi:10.1016/0957-4166(96)00232-7
(1996)Doi:10.1021/ja304816e
(2012)Doi:10.1021/jo0300035
(2003)